ORTHOCELL LIMITED (OCC)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
OCC - ORTHOCELL LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.06
Index:
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.06
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.365
17 Apr |
OPEN $0.38 |
HIGH $0.38 |
136,781 LOW $0.37 |
-0.010| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -3.2 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 4.2 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 3.1 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 14.6 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -147.26 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -77.84 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -74.28 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -18.51 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -77.84 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -120.42 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 14.0 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 25 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 11.23 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.6 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 14.88 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 1 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 13 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 8 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
OCC STOCK CHART
FNArena News on OCC
| 1 |
Australian Broker Call *Extra* Edition – Feb 16, 2024Feb 16 2024 - Daily Market Reports |
| 2 |
Australian Broker Call *Extra* Edition – Nov 15, 2023Nov 15 2023 - Daily Market Reports |
| 3 |
Australian Broker Call *Extra* Edition – Oct 18, 2023Oct 18 2023 - Daily Market Reports |
| 4 |
Australian Broker Call *Extra* Edition – Dec 21, 2022Dec 21 2022 - Daily Market Reports |
| 5 |
Dr Boreham’s Crucible: OrthocellJul 26 2022 - Small Caps |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
| 2 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
| 3 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
| 4 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
| 5 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |
| 6 |
Dr Boreham’s Crucible: ImugeneDec 11 2023 - Small Caps |
| 7 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
| 8 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
| 9 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |
| 10 |
Dr Boreham’s Crucible: Cleo DiagnosticsAug 30 2023 - Small Caps |